SEC Comment Letter for Clearside Biomedical, Inc. (CLSD) (CIK 0001539029) (CLSDQ) — Jan 15, 2020
Clearside Biomedical, Inc. (CLSD) (CIK 0001539029)
Date: Jan. 15, 2020 · CIK: 0001539029 · Accession: 0000000000-20-000364
AI Filing Summary & Sentiment
File numbers found in text: 333-235880
Letter
January 15, 2020 George Lasezkay, Pharm.D., J.D. Chief Executive Officer Clearside Biomedical, Inc. 900 North Point Parkway, Suite 200 Alpharetta, Georgia 30005 Re:Clearside Biomedical, Inc. Registration Statement on Form S-3 Filed January 10, 2020 File No. 333-235880 Dear Dr. Lasezkay: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brent B. Siler, Esq.
Show Raw Text
January 15, 2020
George Lasezkay, Pharm.D., J.D.
Chief Executive Officer
Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200
Alpharetta, Georgia 30005
Re:Clearside Biomedical, Inc.
Registration Statement on Form S-3
Filed January 10, 2020
File No. 333-235880
Dear Dr. Lasezkay:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brent B. Siler, Esq.